Immunogenicity and Immune Response
Immunogenicity is the capacity of a vaccine to elicit an immune response, and this area orients the reader to how that response unfolds: how antigens are recognized, how antibodies and effector T cells are generated, how immunological memory is laid down, and how these laboratory readouts relate to protection in the field. It frames immunogenicity as the bridge between what a vaccine contains and the clinical protection it ultimately confers.
Definition
Immunogenicity is the ability of an antigen or vaccine to provoke an adaptive immune response; the immune response to vaccination comprises the coordinated innate, humoral, and cellular events that produce effector molecules and cells and establish memory against the targeted pathogen.
Scope
The area gathers the immune mechanisms that determine whether and how a vaccine works: humoral (antibody) responses, cellular (T-cell) responses, the formation and persistence of immunological memory, and the distinction between immunogenicity measured in the laboratory and efficacy or effectiveness measured in trials and populations. It is a reference-educational overview of mechanisms and concepts, not a guide to choosing, scheduling, or administering vaccines.
Sub-topics
Core questions
- What components of the immune response does a given vaccine elicit, and which of them correlate with protection?
- How are antibody and T-cell responses generated, measured, and maintained after vaccination?
- How does laboratory immunogenicity relate to clinically measured efficacy and effectiveness?
- What determines the durability of vaccine-induced immunity and the need for boosting?
Key concepts
- Immunogenicity
- Correlates of protection
- Humoral (antibody) immunity
- Cellular (T-cell) immunity
- Immunological memory
- Vaccine efficacy versus effectiveness
- Durability and waning of immunity
Mechanisms
A vaccine antigen is taken up and presented by antigen-presenting cells, which activate antigen-specific CD4+ helper T cells; these in turn help B cells in germinal centres to undergo affinity maturation and class switching, producing high-affinity antibodies and long-lived plasma cells and memory B cells, while CD8+ and effector CD4+ T cells provide cellular immunity. The quantity, quality, and durability of these responses define a vaccine's immunogenicity. Plotkin's synthesis of correlates of protection shows that, for many vaccines, a measurable immune marker (often an antibody titre) can stand in for protection, while others depend more heavily on cellular immunity or on memory that is recalled on exposure.
Clinical relevance
Understanding immunogenicity helps clinicians and public-health readers interpret what an antibody titre or T-cell assay does and does not say about protection, and why some vaccines need boosters while others confer durable immunity. This area describes how vaccine-induced immunity is generated and evaluated; it is background for appraising evidence and is not a basis for individual vaccination decisions, which follow current schedules and guidelines.
Epidemiology
The relationship between immunogenicity and population protection is the foundation of vaccine evaluation: established correlates of protection allow new or modified vaccines to be licensed on immunogenicity data, while effectiveness studies confirm protection under real-world conditions. Amanna and colleagues' long-term follow-up of antibody responses illustrates how durably humoral immunity can persist after natural infection or vaccination, informing expectations about waning and boosting.
History
The concept that a vaccine's protective value can be predicted from a measurable immune response matured through the twentieth century as serological assays were standardized and antibody thresholds were linked to protection for diseases such as diphtheria, tetanus, and measles. Plotkin's reviews consolidated the modern framework of correlates of protection, while advances in cellular immunology extended attention beyond antibodies to T-cell responses and memory.
Key figures
- Stanley Plotkin
- Martin Bachmann
- Mark Slifka
Related topics
Seminal works
- plotkin-2010
- plotkin-2008
- amanna-2007
Frequently asked questions
- What is the difference between immunogenicity and efficacy?
- Immunogenicity is the immune response a vaccine elicits, usually measured in the laboratory as antibody titres or T-cell readouts; efficacy is the protection against disease the vaccine confers, measured in clinical trials. A vaccine can be immunogenic yet only protective if its immune markers actually correlate with protection.
- Why do some vaccines require boosters?
- Vaccine-induced immunity can wane over time as antibody levels fall and memory responses are not re-stimulated; boosters re-engage immunological memory to restore protective levels. The need for boosting depends on how durable the original response and its correlate of protection are.